These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22111741)

  • 1. Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia.
    Bulloch MN; Pinner NA
    Expert Rev Clin Pharmacol; 2010 Sep; 3(5):601-12. PubMed ID: 22111741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaptans: a promising therapy in the management of advanced cirrhosis.
    Ginès P
    J Hepatol; 2007 Jun; 46(6):1150-2. PubMed ID: 17445935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan.
    Friedman B; Cirulli J
    J Crit Care; 2013 Apr; 28(2):219.e1-12. PubMed ID: 22884529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB; Alemayehu A
    Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
    J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
    Decaux G
    J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan for the treatment of heart failure: a review of the literature.
    Ambrosy A; Goldsmith SR; Gheorghiade M
    Expert Opin Pharmacother; 2011 Apr; 12(6):961-76. PubMed ID: 21401442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
    Gaglio P; Marfo K; Chiodo J
    Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A; Menon MC
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
    J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2013 Sep; 34(6):336-47. PubMed ID: 23794414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan, hyponatremia, and heart failure.
    Zmily HD; Daifallah S; Ghali JK
    Int J Nephrol Renovasc Dis; 2011; 4():57-71. PubMed ID: 21694950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan and its potential in the treatment of hyponatremia.
    Dixon MB; Lien YH
    Ther Clin Risk Manag; 2008 Dec; 4(6):1149-55. PubMed ID: 19337422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V2 receptor antagonist; tolvaptan.
    Yi JH; Shin HJ; Kim HJ
    Electrolyte Blood Press; 2011 Dec; 9(2):50-4. PubMed ID: 22438856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.
    Ferguson-Myrthil N
    Cardiol Rev; 2010; 18(6):313-21. PubMed ID: 20926941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.